CENTER FOR NEUROLOGIC STUDY

Address
7590 FAY AVENUE No 517
LA JOLLA, CA 92037
Contact
Website: http://cnsonline.org
Phone: +1 (858) 455-5463
Nonprofit
NTEE: G96 - Neurology, Neuroscience
EIN: 95-3374771

Mission

THE CENTER FOR NEUROLOGIC STUDY HAS A STRAIGHTFORWARD MISSION: ADVANCE THE CAUSE OF PATIENTS WITH DISORDERS OF THE NERVOUS SYSTEM. THIS HAS BEEN ACCOMPLISHED THROUGH PROVIDING PATIENT AND FAMILY SUPPORT,DRUG DEVELOPMENT AND CLINICAL RESEARCH.
 20172016201520142013
Basic features of the organization
Year of formation1979
Subsection code03
PF filing required0    
Metropolitan statistical area7320
Form of organization
CorporationTrue
Human resources, including compensation
Summary compensation info
Total compensation of current key personnel$100,000.00$100,000.00$77,083.00$75,000.00$75,000.00
Sum of reportable (W2/1099) compensation$100,000.00$539,583.00$75,000.00$95,000.00$75,000.00
Number of employees22032
Number of people compensated >$100k01000
Number of volunteers00000
Number of highly compensated contractors0000 
Personnel
Bakst, Isaac
Title    DIRECTOR
Name of key/compensated person    ISAAC BAKST MD
Position of compensated person
Current individual trustee or director    True
Average hours per week working for org    1.00
Reportable compensation from org    $0.00
Other comp, non-reportable, from org and related orgs    $0.00
Corresponding comp from related orgs
Reportable compensation from related orgs     $0.00
Barbi, Luci
Title DIRECTORDIRECTORDIRECTORDIRECTOR
Name of key/compensated person LUCI BARBILUCI BARBILUCI BARBILUCI BARBI
Position of compensated person
Current individual trustee or director TrueTrueTrueTrue
Average hours per week working for org 0.300.300.300.30
Reportable compensation from org $0.00$0.00$0.00$0.00
Other comp, non-reportable, from org and related orgs $0.00$0.00$0.00$0.00
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00$0.00$0.00$0.00
Bordiner, Steve
Title   DIRECTOR 
Name of key/compensated person   STEVE BORDINER 
Position of compensated person
Current individual trustee or director   True 
Average hours per week working for org   0.30 
Reportable compensation from org   $0.00 
Other comp, non-reportable, from org and related orgs   $0.00 
Corresponding comp from related orgs
Reportable compensation from related orgs    $0.00 
Bordner, Steve
TitleDIRECTORDIRECTORDIRECTOR  
Name of key/compensated personSTEVE BORDNERSTEVE BORDNERSTEVE BORDNER  
Position of compensated person
Current individual trustee or directorTrueTrueTrue  
Average hours per week working for org0.300.300.30  
Reportable compensation from org$0.00$0.00$0.00  
Other comp, non-reportable, from org and related orgs$0.00$0.00$0.00  
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00  
Broido, Jeffrey
Title    DIRECTOR
Name of key/compensated person    JEFFREY BROIDO
Position of compensated person
Current individual trustee or director    True
Average hours per week working for org    0.30
Reportable compensation from org    $0.00
Other comp, non-reportable, from org and related orgs    $0.00
Corresponding comp from related orgs
Reportable compensation from related orgs     $0.00
Cutchin, David
TitleDIRECTOR    
Name of key/compensated personDAVID LOUIS CUTCHIN PHD    
Position of compensated person
Current individual trustee or directorTrue    
Average hours per week working for org0.50    
Reportable compensation from org$0.00    
Other comp, non-reportable, from org and related orgs$0.00    
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00    
Kaye, Randall
TitleDIRECTOR    
Name of key/compensated personRANDALL KAYE MD    
Position of compensated person
Current individual trustee or directorTrue    
Average hours per week working for org0.30    
Reportable compensation from org$0.00    
Other comp, non-reportable, from org and related orgs$0.00    
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00    
Licht, Jonathan
Title   FORMER SECRETARYSECRETARY
Name of key/compensated person   JONATHAN LICHT MDJONATHAN LICHT MD
Position of compensated person
Current individual trustee or director    True
Average hours per week working for org   0.008.00
Reportable compensation from org   $20,000.00$0.00
Other comp, non-reportable, from org and related orgs   $0.00$0.00
Corresponding comp from related orgs
Reportable compensation from related orgs    $0.00$68,185.00
Myers, Kathleen
TitleSECRETARY/TREASURER    
Name of key/compensated personKATHLEEN MYERS    
Position of compensated person
Current individual trustee or directorTrue    
Average hours per week working for org2.00    
Reportable compensation from org$0.00    
Other comp, non-reportable, from org and related orgs$0.00    
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00    
Schweig, Tania
Title SECRETARY/TREASURERSECRETARY/TREASURERSECRETARY/TREASURER 
Name of key/compensated person TANIA SCHWEIGTANIA SCHWEIGTANIA SCHWEIG 
Position of compensated person
Current individual trustee or director TrueTrueTrue 
Average hours per week working for org 0.300.300.30 
Reportable compensation from org $0.00$0.00$0.00 
Other comp, non-reportable, from org and related orgs $0.00$0.00$0.00 
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00$0.00$0.00 
Smith, Daryl
TitleDIRECTOR    
Name of key/compensated personDARYL SMITH    
Position of compensated person
Current individual trustee or directorTrue    
Average hours per week working for org0.50    
Reportable compensation from org$0.00    
Other comp, non-reportable, from org and related orgs$0.00    
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00    
Smith, Richard
TitlePRESIDENTPRESIDENTPRESIDENTPRESIDENTPRESIDENT
Name of key/compensated personRICHARD A SMITH MDRICHARD A SMITH MDRICHARD A SMITH MDRICHARD A SMITH MDRICHARD A SMITH MD
Position of compensated person
Current individual trustee or directorTrueTrueTrueTrueTrue
Average hours per week working for org25.0025.0025.0025.0025.00
Reportable compensation from org$100,000.00$539,583.00$75,000.00$75,000.00$75,000.00
Other comp, non-reportable, from org and related orgs$0.00$0.00$0.00$0.00$0.00
Corresponding comp from related orgs
Reportable compensation from related orgs $0.00$0.00$0.00$0.00$0.00
Thagard, Greg
Title    DIRECTOR
Name of key/compensated person    GREG THAGARD
Position of compensated person
Current individual trustee or director    True
Average hours per week working for org    0.30
Reportable compensation from org    $0.00
Other comp, non-reportable, from org and related orgs    $0.00
Corresponding comp from related orgs
Reportable compensation from related orgs     $0.00
Tse, Yardy
Title DIRECTORDIRECTORDIRECTORDIRECTOR
Name of key/compensated person YARDY TSE MDYARDY TSE MDYARDY TSE MDYARDY TSE MD
Position of compensated person
Current individual trustee or director TrueTrueTrueTrue
Average hours per week working for org 0.300.300.300.30
Reportable compensation from org $0.00$0.00$0.00$0.00
Other comp, non-reportable, from org and related orgs $0.00$0.00$0.00$0.00
Corresponding comp from related orgs
Reportable compensation from related orgs  $0.00$0.00$0.00$0.00
Purpose: mission, activities, & accomplishments
Mission or significant activitiesTO ADVANCE THE CAUSE OF PATIENTS WITH DISORDERS OF THE NERVOUS SYSTEM.TO ADVANCE THE CAUSE OF PATIENTS WITH DISORDERS OF THE NERVOUS SYSTEM.TO ADVANCE THE CAUSE OF PATIENTS WITH DISORDERS OF THE NERVOUS SYSTEM.TO ADVANCE THE CAUSE OF PATIENTS WITH DISORDERS OF THE NERVOUS SYSTEM.TO ADVANCE THE CAUSE OF PATIENTS WITH DISORDERS OF THE NERVOUS SYSTEM.
Program service expenses, total$7,137,000.00$11,425,257.00$185,591.00$1,945,655.00$217,987.00
Programs, including revenue & expenses
COUNSELING SERVICES: CNS PROVIDES PATIENT AND FAMILY COUNSELING, WITHOUT CHARGE, FOR THOSE AFFECTED BY NEUROLOGIC DISORDERS. MOST OF THESE INTERACTIONS ARE CONDUCTED THROUGH PHONE OR INTERNET COMMUNICATION AND SOME THROUGH PARTICIPATION IN PUBLIC FORUMS, SOME SPONSORED BY NATIONAL ORGANIZATIONS SUCH AS THE ALS ASSOCIATION.
Program expenses$10,156.00$18,650.00$9,179.00$6,377.00$9,900.00
Program descriptionCOUNSELING SERVICES: CNS PROVIDES PATIENT AND FAMILY COUNSELING, WITHOUT CHARGE, FOR THOSE AFFECTED BY NEUROLOGIC DISORDERS. MOST OF THESE INTERACTIONS ARE CONDUCTED THROUGH PHONE OR INTERNET COMMUNICATION AND SOME THROUGH PARTICIPATION IN PUBLIC FORUMS, SOME SPONSORED BY NATIONAL ORGANIZATIONS SUCH AS THE ALS ASSOCIATION.COUNSELING SERVICES: CNS PROVIDES PATIENT AND FAMILY COUNSELING, WITHOUT CHARGE, FOR THOSE AFFECTED BY NEUROLOGIC DISORDERS. ABOUT HALF OF THESE INTERACTIONS ARE CONDUCTED AT THE CENTER, OTHERS THROUGH PHONE OR INTERNET COMMUNICATION AND SOME THROUGH PARTICIPATION IN PUBLIC FORUMS, SOME SPONSORED BY NATIONAL ORGANIZATIONS SUCH AS THE ALS ASSOCIATION.COUNSELING SERVICES: CNS PROVIDES PATIENT AND FAMILY COUNSELING, WITHOUT CHARGE, FOR THOSE AFFECTED BY NEUROLOGIC DISORDERS. ABOUT HALF OF THESE INTERACTIONS ARE CONDUCTED AT THE CENTER, OTHERS THROUGH PHONE OR INTERNET COMMUNICATION AND SOME THROUGH PARTICIPATION IN PUBLIC FORUMS, SOME SPONSORED BY NATIONAL ORGANIZATIONS SUCH AS THE ALS ASSOCIATION.COUNSELING SERVICES: CNS PROVIDES PATIENT AND FAMILY COUNSELING, WITHOUT CHARGE, FOR THOSE AFFECTED BY NEUROLOGIC DISORDERS. ABOUT HALF OF THESE INTERACTIONS ARE CONDUCTED AT THE CENTER, OTHERS THROUGH PHONE OR INTERNET COMMUNICATION AND SOME THROUGH PARTICIPATION IN PUBLIC FORUMS, SOME SPONSORED BY NATIONAL ORGANIZATIONS SUCH AS THE ALS ASSOCIATION.COUNSELING SERVICES: CNS PROVIDES PATIENT AND FAMILY COUNSELING, WITHOUT CHARGE, FOR THOSE AFFECTED BY NEUROLOGIC DISORDERS. ABOUT HALF OF THESE INTERACTIONS ARE CONDUCTED AT THE CENTER, OTHERS THROUGH PHONE OR INTERNET COMMUNICATION AND SOME THROUGH PARTICIPATION IN PUBLIC FORUMS, SOME SPONSORED BY NATIONAL ORGANIZATIONS SUCH AS THE ALS ASSOCIATION.
PUBLIC EDUCATION: RESEARCH CONDUCTED AT CNS HAS BEEN PRESENTED PUBLICALLY AT MEDICAL AND SCIENTIFIC MEETINGS AND PUBLISHED IN LEADING SCIENTIFIC JOURNALS. THESE ACTIVITIES HAVE BEEN REPORTED UPON IN LOCAL AND NATIONAL MEDIA, INCLUDING NBC AND CNN TELEVISION,THE SAN DIEGO UNION TRIBUNE, THE LOS ANGELES AND NEW YORK TIMES AND SCIENTIFIC AMERICAN. CNS ALSO PROVIDES INFORMATION ABOUT NEUROLOGICAL DISEASES TO PATIENTS, PHYSICIANS AND THE GENERAL PUBLIC VIA IT'S WEBSITE (CNSONLINE.ORG). ADDITIONALY CNS IS INVOLVED IN ORGANIZING AN ANNUAL CONFERENCE ON AMYOTROPHIC LATERAL SCLEROSIS IN COLLABORATION WITH ACADEMIC INSTITUTIONS IN CALIFORNIA (CALIFORNIA ALS SUMMIT). CNS ALLOCATES APPROXIMATELY 5% OF ITS EXPENSES TO PUBLIC EDUCATION.
Program expenses$10,156.00$18,650.00$9,179.00$6,377.00$9,900.00
Program descriptionPUBLIC EDUCATION: RESEARCH CONDUCTED AT CNS HAS BEEN PRESENTED PUBLICALLY AT MEDICAL AND SCIENTIFIC MEETINGS AND PUBLISHED IN LEADING SCIENTIFIC JOURNALS. THESE ACTIVITIES HAVE BEEN REPORTED UPON IN LOCAL AND NATIONAL MEDIA, INCLUDING NBC AND CNN TELEVISION,THE SAN DIEGO UNION TRIBUNE, THE LOS ANGELES AND NEW YORK TIMES AND SCIENTIFIC AMERICAN. CNS ALSO PROVIDES INFORMATION ABOUT NEUROLOGICAL DISEASES TO PATIENTS, PHYSICIANS AND THE GENERAL PUBLIC VIA IT'S WEBSITE (CNSONLINE.ORG). ADDITIONALY CNS IS INVOLVED IN ORGANIZING AN ANNUAL CONFERENCE ON AMYOTROPHIC LATERAL SCLEROSIS IN COLLABORATION WITH ACADEMIC INSTITUTIONS IN CALIFORNIA (CALIFORNIA ALS SUMMIT). CNS ALLOCATES APPROXIMATELY 5% OF ITS EXPENSES TO PUBLIC EDUCATION.PUBLIC EDUCATION: RESEARCH CONDUCTED AT CNS HAS BEEN PRESENTED PUBLICALLY AT MEDICAL AND SCIENTIFIC MEETINGS AND PUBLISHED IN LEADING SCIENTIFIC JOURNALS. THESE ACTIVITIES HAVE BEEN REPORTED UPON IN LOCAL AND NATIONAL MEDIA, INCLUDING NBC AND CNN TELEVISION AND THE LOS ANGELES AND NEW YORK TIMES. CNS ALSO PROVIDES INFORMATION ABOUT NEUROLOGICAL DISEASES TO PATIENTS, PHYSICIANS AND THE GENERAL PUBLIC VIA IT'S WEBSITE (CNSONLINE.ORG). ADDITIONALY CNS IS INVOLVED IN ORGANIZING AN ANNUAL CONFERENCE ON AMYOTROPHIC LATERAL SCLEROSIS IN COLLABORATION WITH ACADEMIC INSTITUTIONS IN CALIFORNIA. CNS ALLOCATES APPROXIMATELY 5% OF ITS EXPENSES TO PUBLIC EDUCATION.PUBLIC EDUCATION: RESEARCH CONDUCTED AT CNS HAS BEEN PRESENTED PUBLICALLY AT MEDICAL AND SCIENTIFIC MEETINGS AND PUBLISHED IN LEADING SCIENTIFIC JOURNALS. THESE ACTIVITIES HAVE BEEN REPORTED UPON IN LOCAL AND NATIONAL MEDIA, INCLUDING NBC AND CNN TELEVISION AND THE LOS ANGELES AND NEW YORK TIMES. CNS ALSO PROVIDES INFORMATION ABOUT NEUROLOGICAL DISEASES TO PATIENTS, PHYSICIANS AND THE GENERAL PUBLIC VIA IT'S WEBSITE (CNSONLINE.ORG). ADDITIONALY CNS IS INVOLVED IN ORGANIZING AN ANNUAL CONFERENCE ON AMYOTROPHIC LATERAL SCLEROSIS IN COLLABORATION WITH ACADEMIC INSTITUTIONS IN CALIFORNIA. CNS ALLOCATES APPROXIMATELY 5% OF ITS EXPENSES TO PUBLIC EDUCATION.PUBLIC EDUCATION: RESEARCH CONDUCTED AT CNS HAS BEEN PRESENTED PUBLICALLY AT MEDICAL AND SCIENTIFIC MEETINGS AND PUBLISHED IN LEADING SCIENTIFIC JOURNALS. THESE ACTIVITIES HAVE BEEN REPORTED UPON IN LOCAL AND NATIONAL MEDIA, INCLUDING NBC AND CNN TELEVISION AND THE LOS ANGELES AND NEW YORK TIMES. CNS ALSO PROVIDES INFORMATION ABOUT NEUROLOGICAL DISEASES TO PATIENTS, PHYSICIANS AND THE GENERAL PUBLIC VIA IT'S WEBSITE (CNSONLINE.ORG). ADDITIONALY CNS IS INVOLVED IN ORGANIZING AN ANNUAL CONFERENCE ON AMYOTROPHIC LATERAL SCLEROSIS IN COLLABORATION WITH ACADEMIC INSTITUTIONS IN CALIFORNIA. CNS ALLOCATES APPROXIMATELY 5% OF ITS EXPENSES TO PUBLIC EDUCATION.PUBLIC EDUCATION: RESEARCH CONDUCTED AT CNS HAS BEEN PRESENTED PUBLICALLY AT MEDICAL AND SCIENTIFIC MEETINGS AND PUBLISHED IN LEADING SCIENTIFIC JOURNALS. THESE ACTIVITIES HAVE BEEN REPORTED UPON IN LOCAL AND NATIONAL MEDIA, INCLUDING NBC AND CNN TELEVISION AND THE LOS ANGELES AND NEW YORK TIMES. CNS ALSO PROVIDES INFORMATION ABOUT NEUROLOGICAL DISEASES TO PATIENTS, PHYSICIANS AND THE GENERAL PUBLIC VIA IT'S WEBSITE (CNSONLINE.ORG). ADDITIONALY CNS IS INVOLVED IN ORGANIZING AN ANNUAL CONFERENCE ON AMYOTROPHIC LATERAL SCLEROSIS IN COLLABORATION WITH ACADEMIC INSTITUTIONS IN CALIFORNIA. CNS ALLOCATES APPROXIMATELY 5% OF ITS EXPENSES TO PUBLIC EDUCATION.
RESEARCH: THE PIONEERING WORK OF CNS HAS LED TO NEW TREATMENTS. FOR EXAMPLE, WORK UNDERTAKEN AT CNS PLAYED A ROLE IN THE INTRODUCTION OF INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS. STARTING IN THE 1980'S, THE CENTER PARTICIPATED IN NUMEROUS NATIONAL, EXPERIMENTAL TREATMENT TRIALS INVOLVING AMYOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S DISEASE, NEUROPATHY, ETC. PARTICULARLY NOTEWORTHY IS WORK AT CNS THAT LED TO THE DISCOVERY OF NUEDEXTA WHICH HAS BEEN SUCCESSFUL IN NUMEROUS TREATMENT TRIALS AND WAS APPROVED FOR USE IN THE UNITED STATES IN OCTOBER 2010 AND IN EUROPE IN 2013. REMARKABLY, THE DRUG HAS IMPROVED FUNCTION IN BOTH ALZHEIMER'S DISEASE AND ALS PATIENTS, WITH STUDY RESULTS PUBLISHED IN MAJOR SCIENTIFIC JOURNALS. PIONEERING WORK DONE AT CNS IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA AND IONIS PHARMACEUTICALS IS WIDELY BELIEVED TO BE THE MOST PROMISING STRATEGY FOR TREATING NEURODEGENERATIVE DISEASES SUCH AS HUNTINGTON'S DISEASE AND FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS. THIS STRATEGY INVOLVES THE SYNTHESIS OF SMALL MOLECULES THAT DOWN REGULATE THE EXPRESSION OF MUTANT PROTEINS IN THE BRAIN. THE LATTER RESULTS WERE PRESENTED AT THE 2018 ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY. CNS ALLOCATES APPROXIMATELY 70% OF ITS EXPENSES TO RESEARCH.
Program expenses$7,116,688.00$11,387,957.00$167,233.00$1,932,901.00$198,187.00
Program descriptionRESEARCH: THE PIONEERING WORK OF CNS HAS LED TO NEW TREATMENTS. FOR EXAMPLE, WORK UNDERTAKEN AT CNS PLAYED A ROLE IN THE INTRODUCTION OF INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS. STARTING IN THE 1980'S, THE CENTER PARTICIPATED IN NUMEROUS NATIONAL, EXPERIMENTAL TREATMENT TRIALS INVOLVING AMYOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S DISEASE, NEUROPATHY, ETC. PARTICULARLY NOTEWORTHY IS WORK AT CNS THAT LED TO THE DISCOVERY OF NUEDEXTA WHICH HAS BEEN SUCCESSFUL IN NUMEROUS TREATMENT TRIALS AND WAS APPROVED FOR USE IN THE UNITED STATES IN OCTOBER 2010 AND IN EUROPE IN 2013. REMARKABLY, THE DRUG HAS IMPROVED FUNCTION IN BOTH ALZHEIMER'S DISEASE AND ALS PATIENTS, WITH STUDY RESULTS PUBLISHED IN MAJOR SCIENTIFIC JOURNALS. PIONEERING WORK DONE AT CNS IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA AND IONIS PHARMACEUTICALS IS WIDELY BELIEVED TO BE THE MOST PROMISING STRATEGY FOR TREATING NEURODEGENERATIVE DISEASES SUCH AS HUNTINGTON'S DISEASE AND FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS. THIS STRATEGY INVOLVES THE SYNTHESIS OF SMALL MOLECULES THAT DOWN REGULATE THE EXPRESSION OF MUTANT PROTEINS IN THE BRAIN. THE LATTER RESULTS WERE PRESENTED AT THE 2018 ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY. CNS ALLOCATES APPROXIMATELY 70% OF ITS EXPENSES TO RESEARCH.RESEARCH: THE PIONEERING WORK OF CNS HAS LED TO NEW TREATMENTS. FOR EXAMPLE, WORK UNDERTAKEN AT CNS PLAYED A ROLE IN THE INTRODUCTION OF INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS. STARTING IN THE 1980'S, THE CENTER PARTICIPATED IN NUMEROUS NATIONAL, EXPERIMENTAL TREATMENT TRIALS INVOLVING AMYOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S DISEASE, NEUROPATHY, ETC. PARTICULARLY NOTEWORTHY IS WORK AT CNS THAT LED TO THE DISCOVERY OF NUEDEXTA WHICH HAS BEEN SUCCESSFUL IN NUMEROUS TREATMENT TRIALS AND WAS APPROVED FOR USE IN THE UNTIED STATES IN OCTOBER 2010 AND IN EUROPE IN 2013. PIONEERING WORK DONE AT CNS IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA AND ISIS PHARMACEUTICALS IS WIDELY BELIEVED TO BE THE MOST PROMISING STRATEGY FOR TREATING NEURODEGENERATIVE DISEASES SUCH AS HUNTINGTON'S DISEASE AND FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS. THIS STRATEGY INVOLVES THE SYNTHESIS OF SMALL MOLECULES THAT DOWN REGULATE THE EXPRESSION OF MUTANT PROTEINS IN THE BRAIN. CNS ALLOCATES APPROXIMATELY 70% OF ITS EXPENSES TO RESEARCH.RESEARCH: THE PIONEERING WORK OF CNS HAS LED TO NEW TREATMENTS. FOR EXAMPLE, WORK UNDERTAKEN AT CNS PLAYED A ROLE IN THE INTRODUCTION OF INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS. STARTING IN THE 1980'S, THE CENTER PARTICIPATED IN NUMEROUS NATIONAL, EXPERIMENTAL TREATMENT TRIALS INVOLVING AMYOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S DISEASE, NEUROPATHY, ETC. PARTICULARLY NOTEWORTHY IS WORK AT CNS THAT LED TO THE DISCOVERY OF NUEDEXTA WHICH HAS BEEN SUCCESSFUL IN NUMEROUS TREATMENT TRIALS AND WAS APPROVED FOR USE IN THE UNTIED STATES IN OCTOBER 2010 AND IN EUROPE IN 2013. PIONEERING WORK DONE AT CNS IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA AND ISIS PHARMACEUTICALS IS WIDELY BELIEVED TO BE THE MOST PROMISING STRATEGY FOR TREATING NEURODEGENERATIVE DISEASES SUCH AS HUNTINGTON'S DISEASE AND FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS. THIS STRATEGY INVOLVES THE SYNTHESIS OF SMALL MOLECULES THAT DOWN REGULATE THE EXPRESSION OF MUTANT PROTEINS IN THE BRAIN. CNS ALLOCATES APPROXIMATELY 70% OF ITS EXPENSES TO RESEARCH.RESEARCH: THE PIONEERING WORK OF CNS HAS LED TO NEW TREATMENTS. FOR EXAMPLE, WORK UNDERTAKEN AT CNS PLAYED A ROLE IN THE INTRODUCTION OF INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS. STARTING IN THE 1980'S, THE CENTER PARTICIPATED IN NUMEROUS NATIONAL, EXPERIMENTAL TREATMENT TRIALS INVOLVING AMYOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S DISEASE, NEUROPATHY, ETC. PARTICULARLY NOTEWORTHY IS WORK AT CNS THAT LED TO THE DISCOVERY OF NUEDEXTA WHICH HAS BEEN SUCCESSFUL IN NUMEROUS TREATMENT TRIALS AND WAS APPROVED FOR USE IN THE UNTIED STATES IN OCTOBER 2010 AND IN EUROPE IN 2013. PIONEERING WORK DONE AT CNS IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA AND ISIS PHARMACEUTICALS IS WIDELY BELIEVED TO BE THE MOST PROMISING STRATEGY FOR TREATING NEURODEGENERATIVE DISEASES SUCH AS HUNTINGTON'S DISEASE AND FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS. THIS STRATEGY INVOLVES THE SYNTHESIS OF SMALL MOLECULES THAT DOWN REGULATE THE EXPRESSION OF MUTANT PROTEINS IN THE BRAIN. CNS ALLOCATES APPROXIMATELY 70% OF ITS EXPENSES TO RESEARCH.RESEARCH: THE PIONEERING WORK OF CNS HAS LED TO NEW TREATMENTS. FOR EXAMPLE, WORK UNDERTAKEN AT CNS PLAYED A ROLE IN THE INTRODUCTION OF INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS. STARTING IN THE 1980'S, THE CENTER PARTICIPATED IN NUMEROUS NATIONAL, EXPERIMENTAL TREATMENT TRIALS INVOLVING AMYOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S DISEASE, NEUROPATHY, ETC. PARTICULARLY NOTEWORTHY IS WORK AT CNS THAT LED TO THE DISCOVERY OF NUEDEXTA WHICH HAS BEEN SUCCESSFUL IN NUMEROUS TREATMENT TRIALS AND WAS APPROVED FOR USE IN THE UNTIED STATES IN OCTOBER 2010 AND IN EUROPE IN 2013. PIONEERING WORK DONE AT CNS IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA AND ISIS PHARMACEUTICALS IS WIDELY BELIEVED TO BE THE MOST PROMISING STRATEGY FOR TREATING NEURODEGENERATIVE DISEASES SUCH AS HUNTINGTON'S DISEASE AND FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS. THIS STRATEGY INVOLVES THE SYNTHESIS OF SMALL MOLECULES THAT DOWN REGULATE THE EXPRESSION OF MUTANT PROTEINS IN THE BRAIN. CNS ALLOCATES APPROXIMATELY 70% OF ITS EXPENSES TO RESEARCH.
Financial data
Revenue
Total revenue$9,797,919.00$36,157,664.00$73,085.00$3,778,252.00$1,405,132.00
Revenue from contributions (total)$18.00$10,000.00$4,582.00$14,760.00$14,759.00
Investment income, current yr$797,901.00$97,664.00$68,503.00$56,385.00$4,623.00
Total revenue from grants, etc., current yr$18.00$10,000.00$4,582.00$14,760.00$14,759.00
Total unrelated business revenue$0.00$0.00$0.00$0.00$0.00
Other revenue, current yr$9,000,000.00$36,050,000.00$0.00$3,707,107.00$0.00
Net unrelated business taxable revenue$0.00$0.00$0.00$0.00$0.00
Program service revenue (total)  $0.00$0.00$1,385,750.00
Gross receipts$9,797,919.00$37,003,640.00$1,068,670.00$3,786,252.00$1,405,132.00
Sources of contributions
Revenue from all other contributions$18.00$10,000.00$4,582.00$14,760.00$14,759.00
Other types of revenue
Royalties (total)$9,000,000.00$36,050,000.00 $3,707,107.00 
Income from dividends, interest, and similar investments$590,349.00$144,476.00$125,473.00$44,936.00$4,623.00
Net rental income  $0.00$0.00$0.00
Expense categories (totals)
Total functional expenses: sum of all$16,279,638.00$12,005,367.00$450,603.00$1,997,496.00$257,588.00
Total functional expenses: program service $7,137,000.00$11,425,257.00$185,591.00$1,945,655.00$217,987.00
Total functional expenses: management and general$9,142,638.00$580,110.00$265,012.00$51,841.00$39,601.00
Total functional expenses: fundraising$0.00$0.00$0.00$0.00$0.00
Fees for services
Legal fees (total)$9,004,873.00$503,836.00$228,297.00$9,520.00$2,763.00
Fundraising service fees (total)$0.00$0.00$0.00$0.00$0.00
Investment management fees (total)$97,140.00    
Assets and liabilities
Total assets$24,942,395.00$28,203,872.00$3,979,174.00$4,484,623.00$2,045,244.00
Total assets, beginning of year$28,203,872.00$3,979,174.00$4,484,623.00$2,999,712.00$901,560.00
Total liabilities$1,485,067.00$56,235.00$49,720.00$181,948.00$823.00
Total liabilities, beginning of year$56,235.00$49,720.00$181,948.00$485,627.00$4,683.00
Unrestricted net assets, end of yr$23,457,328.00$28,147,637.00$3,929,454.00$4,302,675.00 
Net assets$23,457,328.00$28,147,637.00$3,929,454.00$4,302,675.00$2,044,421.00
Net assets, beginning of year$28,147,637.00$3,929,454.00$4,302,675.00$2,514,085.00$896,877.00
Other assets$1,900.00$1,900.00$1,900.00$1,900.00$5,900.00
Investments: other securities$253,103.00$19,677,285.00$1,000,000.00$1,000,000.00 
Investments: publicly traded securities$1,009,039.00$2,054,652.00$2,509,849.00$1,007,834.00$8,000.00
Cash: non-interest bearing$149,070.00$266,731.00$51,893.00$754,308.00$128,313.00
Cash: non-interest bearing, beginning of year$266,731.00$51,893.00$754,308.00$128,313.00$82,316.00
Other financial variables
Revenue less expenses-$6,481,719.00$24,152,297.00-$377,518.00$1,780,756.00$1,147,544.00
Advertising (total)$3,560.00    
Savings & temp cash investment$23,523,625.00$6,195,744.00$405,591.00$1,404,850.00$1,902,335.00
Accounts receivable, net  $5,833.00$312,699.00 
Accounts payable & accrued expenses$1,485,067.00$56,235.00$49,720.00$181,948.00$823.00
Total net assets or fund balances$23,457,328.00$28,147,637.00$3,929,454.00$4,302,675.00$2,044,421.00
Depreciation, depletion, amortization$194.00$779.00$124.00$653.00$463.00
Governance and accountability
Number of voting members55556
Number of independent voting members44444
Financial sheets audited   True 
Relationships among key personnel   TrueTrue
Accrual accountingTrueTrueTrueTrueTrue
Tax year start date2016-07-012015-07-012014-07-012013-07-012012-07-01
Tax year end date2017-06-012016-06-012015-06-012014-06-012013-06-01
Indicators for schedules (selected)
Business transaction with entity owner    True
Business transaction with family member   True 
Business transaction with employee   True 
Lobbied True   
Grants to domestic org/gov't >$5kTrue    
Org has controlled entity   TrueTrue
Org transacted with controlled entity   True 
Metadata about the filing
E-return type: 990, 990EZ, or 990PF990990990990990
Reason for form submission
Address change    True
Date e-filing submitted2018-06-212017-09-212016-08-102015-08-262014-03-21
IRS schema version2016v3.02015v3.02014v6.02013v4.02012v2.1
Filing identifier201801349349306135201731339349300303201631379349307323201511389349300126201400459349301145
Use these data in your project Benchmark this organization against its peers